A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
Sponsor
Merck Sharp & Dohme LLC (Industry)
Overall Status
Completed
CT.gov ID
NCT00005921
Collaborator
(none)
18
1
Study Details
Study Description
Brief Summary
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| N/A |
Detailed Description
In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.
Study Design
Study Type:
Interventional
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria
You may be eligible for this study if you:
- Are an 18- to 65-year-old man with candidal esophagitis.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Gary Calandra | Rahway | New Jersey | United States | 07065 |
Sponsors and Collaborators
- Merck Sharp & Dohme LLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00005921
Other Study ID Numbers:
- 267A
- 007-00
First Posted:
Aug 31, 2001
Last Update Posted:
Jun 24, 2005
Last Verified:
Jun 1, 2000
Keywords provided by ,
,
Additional relevant MeSH terms: